Curriculum

 

PRESENT POSITION

Assistant professor (RTDa) with a fixed-term employment contract at the Department of Translational Medicine of the University of Ferrara, since July 2022. Scientific field reference 06/MEDS-10 - MEDS-10/B - Infectious Diseases

MD specialisti in Infectious Disease at Ferrara Hospital (Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara)



MAIN UNIVERSITY DEGREE

Degree in Medicine and Surgery at the Faculty of Medicine and Surgery of University of Ferrara (July 2003)

 

POST GRADUATE EDUCATION/SPECIALIZATION/TRAINING

Specialization in Infectious Diseases at University of Ferrara (October 2007)



SPOKEN LANGUAGES

  • Italian (native language)

  • English

 

PREVIOUS APPOINTMENTS

  • Physician on a fellowship (February 2008-January 2014) at the Infectious Diseases Unit of the Ferrara Hospital (AzOspFe)

  • MD with a fixed-term employment contract (January 2014-October 2014) at the Infectious Diseases Unit of the Ferrara Hospital (AzOspFe)

  • Research fellow at the Department of Medical Sciences of the University of Ferrara (March 2015- February 2017), scientific sector MED/17, associated with freelance contract as MD Infectious diseases Specialist at Ferrara Hospital

  • Research fellow at the Department of Translational Medicine of the University of Ferrara (September 2020-May 2021), scientific sector MED/17, associated with freelance contract as MD Infectious diseases Specialist at Ferrara Hospital

 

 

CLINICAL MANAGEMENT ACTIVITIES

  • Hospital Representative AIDS Commission for AzOspFe and AUSLFE since March 2024

  • Representative at AIDS Provincial Commission for the city of Ferrara since March 2024

  • Representative for the City of Ferrara at Regional AIDS Commission since March 2024

  • Member of “Tavolo di Lavoro Permanente contrasto HIV/AIDS (Ferrara)” since November 2022

  • Head of the HIV/AIDS Section (Infectious Diseases Unit, Ferrara Hospital, AzOspFe) since December 2021





TEACHING ACTIVITIES

Teaching activities at the University of Ferrara, scientific sector MEDS-10/B (ex MED/17) as assistant professor:

  • Degree course in Medicine and Surgery: “Patologia infettiva contagiosa emergente” since 2020

  • Degree course in Nurse: “Infermieristica clinica in area medica” (mod. Infectious Diseases) since 2023

  • Degree course in Dental Hygiene: “Malattie Infettive e cutanee” (mod. Infectipous Diseases) since 2024.

 

Teaching activities at the University of Ferrara, scientific sector MEDS-10/B (ex MED/17) as Tutor since 2003.

Assistant thesis supervisor for the faculties of Medicine and Surgery, Nursing, Biotechnologies since 2020

Thesis supervisor for the faculties of Medicine and Surgery and Nursing since 2021.



Teaching activities as Infectious Diseases specialist in education and training of healthcare personnel:

  • “Aspetti cardiologici nel paziente con infezione HIV. Integrazione nei percorsi di cura”, Rovigo, December 2009.

  • “XIII Corso AIDS e patologie correlate”, Ferrara, March-June 2010.

  • “Progetto Archivi: implicazioni cardio-metaboliche dell’infezione da HIV”, Ferrara, October 2010.

  • “XIV Corso AIDS e patologie correlate” tenutosi a Ferrara, Febrary-May 2012.

  • Corso “La gestione del paziente HIV positivo con problematiche ossee”, Torino, September 2016.

  • Corso AIDS “Ruolo dell’Infermiere professionale nella gestione del paziente con infezione da HIV/AIDS”, Cona, March 2024

  • Corso AIDS “Ruolo dell’Infermiere professionale nella gestione del paziente con infezione da HIV/AIDS in Ambulatorio”, Cona, November 2024.

 

 

PUBLIC ENGAGEMENT ACTIVITIES

Public engagement activities as coordinator/collaborator in public health:

  • The ONDA project. Open Week salute donna: offerta screening IST. April 2023

  • Researcher's Night 2023. “Infezioni sessualmente trasmesse. Parliamone! Perché la prevenzione inizia dall'informazione”. September 2023

  • “IST, stigma e salute sessuale, c'è un modo migliore per fare prevenzione?” Event. October 2023.

  • Prevention week for HIV: 1° December 2023 “Giornata Mondiale contro l’AIDS-HIV - Proteggiamoci dal virus e dallo stigma”. December 2023

  • Prevention week for HIV for AIDS. March 2024

  • The ONDA project. Open Week salute donna: offerta screening IST (Progetto ONDA). April 2024

  • Public Engagement 2024 UNIFE “Salute e Benessere, un viaggio tra passato, presente e futuro”. May 2024

  • "Screening night" event: somministrazione di test rapidi HIV/sifilide, accompagnata da interventi di carattere informativo sul benessere sessuale e prevenzione di HIV/IST. May 2024

  • Campagna di sensibilizzazione promossa da Fondazione ICONA “Lo stigma non si trasmette più” 2023-2024

  • Researcher's Night 2024. “La salute senza zone d’ombra: facciamo luce sulle Malattie Sessualmente Trasmesse”

  • "Screening night" event: somministrazione di test rapidi HIV/sifilide, accompagnata da interventi di carattere informativo sul benessere sessuale e prevenzione di HIV/IST. October 2024

  • Prevention week for HIV: 1° December 2024 “Giornata Mondiale contro l’AIDS-HIV - Proteggiamoci dal virus e dallo stigma”. December 2024

 

 

CLINICAL RESEARCH EXPERIENCE

COLLABORATION WITH NATIONAL AND INTERNATIONAL RESEARCH GROUPS

  • I.CO.NA Foundation Study Group. “Italian cohort of antiretroviral naive patients”

  • PITER Collaborating Group. “Piattaforma Italiana per lo Studio della Terapia delle Epatiti Virali”

  • Network IRENE “The Italian REgistry of pulmonary Non-tuberculous mycobactEria”

  • FUO-FADOI Register, Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti



COLLABORATION AT ITALIAN NATIONAL INSTITUTE OF HEALTH (ISS) AND EMILIA ROMAGNA REGION (RER) PROJECTS AS COORDINATOR FOR FERRARA CLINICAL CENTRE

  • Sistema di sorveglianza delle nuove diagnosi di infezione da HIV (Centro Nazionale AIDS, ISS)

  • “Informazione ed offerta attiva del Test HIV nell’ambito di un programma di assistenza integrata rivolto ad una popolazione di rifugiati e richiedenti asilo: studio pilota nella Provincia di Ferrara”, in continuità con il Programma per l'integrazione dei cittadini stranieri della Regione Emilia-Romagna “Emilia Romagna terra d’asilo”.

  • Progetto regionale HBV-RER. “Progetto integrato di razionalizzazione delle risorse cliniche e laboratoristiche nel governo clinico dell’infezione da virus dell’epatite B in Emilia Romagna”.

  • Progetto pilota regionale “Offerta Attiva del Test HIV in gruppi di popolazione ad elevato rischio di infezione”, nell’ambito del Piano di prevenzione 2015-2018 della Regione Emilia-Romagna e in particolare del percorso “Anticipare la diagnosi e ridurre la trasmissione di HIV e TB”: centro coordinatore l’U.O.C. di Malattie Infettive dell’Azienda Ospedaliero Universitaria di Ferrara.



NATIONAL MULTICENTER CLINICAL TRIALS

 

National multicenter Clinical trials experience as Principal investigator

  • EDOLAS Study. “Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression Short title: Early DOlutegravir/LAmivudine Switching after virological suppression”

  • HEPAICONA Study. Coorte Italiana di pazienti HIV-HCV Positivi

  • ORCHESTRA Study. “COVID 19 e pazienti fragili: studio osservazionale multicentrico per valutare l’incidenza e le caratteristiche del COVID19 e la risposta alla vaccinazione in pazienti fragili”.

  • ICONA Study. “Italian Cohort Naïve Antiretrovirals-Coorte Italiana di Pazienti HIV Positivi-Naïve”.

  • METHIV Study. Il metabolismo lipidico dei linfociti T come marcatore della progressione della malattia di HIV.

  • Monkey-Icona Study. "Coorte osservazionale Italiana su casi di Monkeypox in una popolazione con rischio percepito elevato per esposizione a patogeni sessualmente trasmessi"

  • Long-ICONA Study. “Effectiveness of long-acting antiretroviral treatment with cabotegravir+rilpivirine (cab+rpv) and patients reported determinants in the icona cohort: the long-icona study”

  • PRIDE Study. “Implementazione di una Coorte italiana di persone in profilassi pre-esposizione a HIV-1 all’interno del network ICONA (Prevention ICONA Dedicated Ensemble)”

 

 

National multicenter Clinical trials experience as sub-investigator/co-investigator:

 

  • COVITAR Study. “A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older”. Protocol Number: RT-CoV-2_01

 

Clinical trials fase II:

ISS T-002 Study. “A Phase II randomized, open label, immunogenicity and safety trial of the vaccine based on the recombinant biologically active HIV-1 Tat protein in anti-Tat negative HIV-1 infected HAART-treated adult subjects”. Coordinatore: Dott.ssa Barbara Ensoli – Istituto Superiore Sanità

  • AVX-301 Study. “A phase 2b/3, randomised, double blind, dose confirming study
    of the safety, efficacy and tolerability of apricitabine versus lamivudine in
    treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase”

 

Clinical trials fase III e IV:

  • TESS Study. “Impact on Bone Mineral Density (BMD) of TDF-sparing Antiretroviral regimens in HIV- positive menopausal women affected by osteopenia: the TEnofovir Sparing Strategy (TESS) study”.

  • TSUNAMI Study. “TranSfUsion of coNvalescent plAsma for the early treatment of pneuMonIa due to SARS-CoV2: a multicenter open label randomized control trial”

 

Clinical trials of therapeutic strategy:

  • InCA Study. “Studio pilota randomizzato per valutare le concentrazioni intracellulari di tenofovir-difosfato in pazienti HIV positivi naive alla terapia antiretrovirale trattati con tenofovir/emtricitabina in associazione ad atazanavir/ritonavir versus efavirenz”. Coordinatore Prof. GP Carosi – Clinica Malattie Infettive e tropicali – Università di Brescia.

  • SNODO Study. “Studio multicentrico, randomizzato, controllato, prospettico, in aperto, per la valutazione dell’efficacia e della tollerabilità dello “switch” ad una HAART basata su nevirapina somministrata secondo due schedule giornaliere in pazienti HIV-1 positivi con viremia plasmatica soppressa”.

  • MONO Study. “Studio randomizzato di confronto tra l’introduzione immediata o differita di un nuovo regime antiretrovirale nel paziente con infezione da HIV non responder: ruolo della monoterapia con lamivudina”. Coordinatore Prof. A. Lazzarin Clinica Malattie Infettive Università Vita e Salute Milano

  • Kamon 1 Study. “Pilot, multicenter, randomized study on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV ARV-Naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon”

  • SKAN Study. “Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with any OBR, in HIV patient with undetectable viral load”

  • EPI 109367 Study. “Prospective epidemiological study of the prevalence of HLA-B 5701 in HIV-1 infected patients”

  • GNOMO (Genotypic Networking Organization for Multicentric Observation) Study. “Profili di efficacia e di fallimento di schemi terapeutici contenenti tenofovir: studio osservazionale multicentrico”

  • RTLP Study. “A prospective randomized, open-label trial of two abacavir/lamivudine-based regimen in late presenter naïve patients (with CD4 count >200 cells/microL – advanced HIV disease)”.

  • Accesso allargato al farmaco BMS 790052 (DACLATASVIR; DCV) in combinazione con SOFOSBUVIR (SOF) per pazienti con infezione cronica da HCV

 

Cohort studies

  • NIA cohor Study. “Studio riguardante pazienti HIV+, già trattati con farmaci appartenenti alle tre classi principali (IP, NRTI, NNRTI), che dovranno iniziare o abbiano già iniziato una terapia con farmaci di diversa classe”.

  • OPERA Study. “Optimized Pegylated interferons Efficacy and anti-Retroviral approach. Studio osservazionale per l’ottimizzazione nella pratica clinica della terapia dell’epatite C nei pazienti sieropositivi per HIV”

 

Observational trials

  • TMC 114 HIV 4042 Study. “Post Authorisation Non-Interventional Study in HIV1-infected patients starting or already in treatment with Darunavir”

  • Project l’Italia in Europa. “Studio nazionale basato su indicatori dell’European Centre for Disease, Prevention and Control”

  • DHIVA Study. “Indagine epidemiologica sulla percezione della depressione in pazienti adulti con infezione da HIV

  • OBS T-002 Study. “Observational study with additional diagnostic procedures on anti-Tat immune response in HIV-1 infected HAART-treated adult subjects “

  • OBS T-003 Study. “Observational study with additional diagnostic procedures on anti-Tat immune response in HIV-1 infected asyntomatic adult subjects “

  • ISS T-002 EF-UP Study. “Observational study for the extended follow-up of the patients enrolled in the phase II therapeutic clinical trials ISS T-002” multicentrico: nuova versione consenso per test genetico”.

 

 

INTERNATIONAL MULTICENTER CLINICAL TRIALS

International multicenter Clinical trials experience as sub-investigator/co-investigator:

 

Clinical trials fase II:

  • AVX-301 Study. “A phase 2b/3, randomised, double blind, dose confirming study
    of the safety, efficacy and tolerability of apricitabine versus lamivudine in
    treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase

 

Clinical trials fase III e IV:

  • BI 1100.1470 ARTEN Study. “Open, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on the same background, in HIV1-infected patients who have received no previous antiretroviral treatment (ARTEN)”

  • BI 1182.16 Study. “An open Label Safety Study of Tipranavir Co-administered with Low-dose Ritonavir (TPV/r) in Patients with Advanced HIV-1 Infection and Limited Treatment Options”.

  • Study 1182.17. “A long term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV 1 infected subjects”

  • CNA109586-ASSERT Study. “Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine administered with Efavirenz in Antiretroviral-Naïve, HIV-1 Infected Adult Subjects”

  • OPTIMAL Study. “Studio ottimizzato di fase III di immunostimolazione con Maraviroc, un antagonista del CCR5, in combinazione con una terapia antiretrovirale (cART) in pazienti con diagnosi tardiva da HIV con un evento definente AIDS e/o conta dei linfociti CD4 inferiore alle 200cells/mm3 (ANRS 146 OPTIMAL)”

  • SPRING 2 Study. “A phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects”

  • ROCKET II Study. “A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects with Raised Cholesterol”

  • TMC125-C214 Study. “Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options”

GEMINI 1 Study. “A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non-Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults”



Participation, as a speaker at international and/or national conferences.

  • “Le nuove strategie terapeutiche: gli inibitori CCR5 nell’ambito dell’infezione da HIV”. Ravenna, November 2011.

  • “PI, focus su efficacy-durability-sequencing: casi clinici e discussione con l’esperto”. Ferrara, March 2012.

  • “Strategee Single Tablet Regimen: simulATion E-learninG ExperiEnce”. Rovigo, June 2012.

  • “Legionelle e Legionellosi, mito e realtà”. Ferrara, September 2012.

  • “Tutoring in HIV”. Ferrara, November 2012.

  • Corso di aggiornamento sulle Epatiti Croniche Virali. Ravenna March 2013.

  • “L’Emilia Romagna verso ICAR”. Bologna, April 2013.

  • “Le infezioni associate alle cure sanitarie”. Ferrara, June 2013.

  • “Infezioni da batteri gram positivi: esperienze a confronto”. Bologna, April 2014.

  • “Sepsi: certezze e controversie nella gestione e nella diagnosi”. Forlì, September 2014.

  • “Infezione occulta HIV/AIDS in medicina interna e specialistica: quando sospettare”. Ferrara, October and December 2014.

  • “Accogliere e curare nuove sfide nel tempo delle migrazioni globali”. Ferrara, June 2016.

  • “La gestione del paziente HIV positivo con problematiche ossee”. Torino, September 2016.

  • “Le malattie Infettive del migrante e del viaggiatore”. Ferrara, November 2016

  • “Infettivologia: una disciplina in evoluzione”. Ferrara, March 2017

  • “Diagnosi precoce e trattamento dell’Epatite C nel paziente utilizzatore di sostanze nell’Emilia orientale. Un approccio razionale per eliminare il virus in un territorio atipico”. Ferrara, Novembre 2021

  • “Masterclass - Il paziente con infezione da HIV difficile da trattare: ruolo della barriera genetica”. Modena, November 2022

  • “Tailoring approaches to treatment of infectious diseases: SIMIT Emilia Romagna”. Modena, November 2024

 

SCIENTIFIC PROFILES

Orcid Id: https://orcid.org/0000-0001-6133-0386